先天性肾上腺增生症患儿因氢化可的松配制错误致医源性库欣综合征
一例21-羟化酶缺乏症先天性肾上腺增生症(CAH)20月龄女童,在接受当地配制药房氢化可的松治疗期间出现生长减速、体重身长比过高、易激惹、面部脂肪增多、多血质及体毛增多,虽减少剂量症状仍持续。药厂分析发现每粒标示1 mg的氢化可的松胶囊实际含量为处方的5至10倍。作者结论:医生须警惕配制药物错误可导致意外不良反应,接受配制糖皮质激素治疗的儿童若出现生长停滞和体重过度增加应怀疑医源性库欣综合征。
要点
- 接受配制氢化可的松的CAH患儿出现生长减速和体重过度增加时应怀疑医源性库欣综合征。
- 配制药物安全性和均一性未经检测,可能含有远超处方剂量的氢化可的松。
- 医生须意识到配制药物错误可能导致未预期的不良反应。
核心结论
- 医生必须意识到配制药物错误可能导致未预期的不良反应。
- 任何接受配制糖皮质激素治疗的儿童若出现生长停滞和体重过度增加,应怀疑医源性库欣综合征。
研究设计与样本
- 病例报告:一例20月龄21-羟化酶缺乏症CAH女童,接受当地配制药房氢化可的松治疗。
- 将处方氢化可的松胶囊送至Sports Medicine Research & Testing Laboratory进行分析。
主要发现
- 患儿在接收配制氢化可的松期间出现生长减速、体重身长比过高、易激惹、面部脂肪增多、多血质及体毛增多。
- 减少氢化可的松剂量后体征和症状仍持续。
- 分析显示每粒标示1 mg的氢化可的松胶囊实际含量为处方剂量及标签标示量的5至10倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Patients with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) require lifelong treatment with glucocorticoids. In growing children, the drug of choice is hydrocortisone. Commercially available hydrocortisone tablets do not conform to very low doses prescribed to infants and toddlers, and compounded hydrocortisone is often dispensed to meet therapeutic needs. However, safety, efficacy, and uniformity of compounded products are not tested. We report a case of Cushing syndrome in a child with CAH who was inadvertently receiving excessive hydrocortisone in compounded form. DESIGN: A 20-month-old girl with CAH developed growth deceleration, excessive weight for length, irritability, increased facial fat, plethora, and excess body hair while receiving hydrocortisone from a local compounding pharmacy. The signs and symptoms persisted despite decreasing hydrocortisone dose. Iatrogenic Cushing syndrome was suspected. The prescribed hydrocortisone capsules were sent for analysis to the Sports Medicine Research & Testing Laboratory, where testing revealed that each 1-mg hydrocortisone capsule contained five to 10 times the dose prescribed and listed on the label. CONCLUSION: Physicians must be aware that errors in compounded medications may lead to unanticipated adverse effects. Iatrogenic Cushing syndrome should be suspected in any child receiving compounded glucocorticoid treatment who develops growth arrest and excess weight gain.
引用
- Barillas JE, Eichner D, Van Wagoner R, et al. Iatrogenic Cushing Syndrome in a Child With Congenital Adrenal Hyperplasia: Erroneous Compounding of Hydrocortisone. J Clin Endocrinol Metab. 2018. PMID: 29029106. doi:10.1210/jc.2017-01595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。